Moneycontrol PRO
HomeNewsBusinessPersonal FinanceMoneycontrol Mutual Fund Summit | Financials emerge as top bet for 2023

Moneycontrol Mutual Fund Summit | Financials emerge as top bet for 2023

Bank stocks remain the market’s darlings on the back of an increase in capital expenditure and the cleaning up of bad loans on their balance sheets.

December 26, 2022 / 18:58 IST

India’s stock markets are not cheap at the moment, but there are pockets of opportunity with good visibility on earnings growth, veteran fund managers said at Moneycontrol’s Mutual Fund Summit. Financials are one such sector.

Currently, the Nifty 50 trades at 20.3x the price-to-earnings ratio, at an 18.8x premium to its historical average of current constituents. While the Nifty has gained over 6 percent this year, the Nifty Bank index has rallied 22 percent, and the Nifty PSU Bank index has advanced 77 percent in this period.

On the back of an increase in capital expenditure and the cleaning up of bad loans on their balance sheets, bank stocks remain the market’s darlings.

“The rally in banks is completely in sync with earnings growth and better asset quality,” said Neelesh Surana of Mirae Asset MF.

Also Read: Moneycontrol Mutual Fund Summit | Only solution to remain profitable is scale, says Nippon Life's Sundeep Sikka

Contrary to popular belief, mutual funds are not overweight on financials.

“Midcap and small-cap funds don’t hold too many financial stocks. And, whatever is present in large-cap funds cannot be more than 40 percent, which is the weightage of financials in the Nifty 50,” said R Srinivasan of SBI Mutual Fund. He too sees MF allocation towards financials increasing in 2023.

Healthcare and pharma emerged as the next big bets among the panelists. Along with Surana and Srinivasan, S Naren of ICICI Prudential MF said he is betting on this defensive sector. In a high-volatility scenario, pharma usually emerges as the go-to sector for traders and investors.

“Pharma stocks have not done well this year, so there could be some bounce back,” said Naren.

The Nifty Pharma index is down over 9 percent so far this year as most stocks had run up significantly in 2020 and 2021 on the back of Covid-19 drugs. According to BofA Securities, pharma generally outperforms the benchmark Nifty in six-month and 12-month horizons following periods of uncertainty.

Also Read: Moneycontrol Mutual Fund Summit | ETFs, index funds have shortcomings like gaps in pricing and NAV: Usha Thorat

On industrials, Surana and Srinivasan were on different ends of the spectrum. While Surana said industrial stocks were expensive, Srinivasan maintained they were good for the long term.

“I don’t think we have the liberty to get out of industrial stocks and get in again. So, we will sit through the underperformance, if there’s any,” said Srinivasan.

BofA Securities, too, is overweight in the sector. In its 2023 market outlook, the foreign brokerage said, “With stable fiscal position, capex spending could continue in CY23, private capex too should accelerate next year. Current underweight positioning of FII, valuation at 22x versus peak of 26x gives us comfort.”

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Shailaja Mohapatra Senior sub-editor, Moneycontrol
first published: Dec 15, 2022 06:45 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347